# ACM Biolabs

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/acm-biolabs

- Industry: Biotechnology
- Headquarters: Singapore, Singapore
- Website: www.acmbiolabs.com
- Total disclosed funding: $6.4M
- Latest round: Series A (Jan 14, 2021)
- Investors on record: 5

## About

Based in Singapore, and founded in 2013 by its CEO, Madhavan Nallani, ACM Biolabs Pte Ltd is a Biotech company engaged in the research and development of therapeutic vaccines for the treatment of infectious diseases. The firm has a subsidiary, ACM Biosciences that was launched in 2020 to cater to the international market. ACM Biolabs also has an office in Basel, Switzerland.

The firm uses its proprietary ACM (artificial cell membrane) polymer-based technology to develop prophylactic and therapeutic vaccines for diseases such as cancer and covid. The firm's product pipeline includes ACM-OO1, which is a second-generation covid vaccine that’s tested to be effective against the disease’s newer variants including delta, and omicron.  The company also offers vaccines for personalized cancer treatments.

## Funding rounds

- Series A, Jan 14, 2021, $3.6M — Efung Capital, San Pacific Investments, Ritz Venture Capital
- Seed, Mar 16, 2016, $2.8M — Nagase Singapore Pte Ltd, NTUitive, San Pacific Investments

## Investors

- Nagase Singapore Pte Ltd — Seed
- NTUitive (https://capitalatlas.ai/funds/ntuitive) — Seed
- San Pacific Investments — Seed, Series A
- Efung Capital (https://capitalatlas.ai/funds/efung-capital) — Series A
- Ritz Venture Capital — Series A